The LNP technology used in Pfizer and Moderna's COVID-19 vaccines has been the subject of patent litigation from a number of biotech firms this year. Now, lawsuits claim that COVID-19 vaccines infringe upon new Alnylam patent.
On Tuesday, Alnylam Pharmaceuticals Inc. increased the stakes in its patent battle with Pfizer Inc. and Moderna Inc. over the COVID-19 vaccines by charging them in federal court in Delaware of violating a recently acquired patent.
The lawsuits (read below) claimed that the messenger-RNA delivery mechanisms used by the vaccinations infringe upon an Alnylam patent on the use of lipid nanoparticles (LNPs) to transport genetic material into human cells. The patent was granted by the USPTO the same day Alnylam filed the complaint.
The LNP technology used in Pfizer and Moderna's COVID-19 vaccines has been the subject of patent litigation from a number of biotech firms this year.
Cambridge, Massachusetts-based In March, Alnylam filed a lawsuit against P...
Full Access
Included:
-
Access to All Articles.
-
One Plan. No Tiers.
-
No Ads.
-
Cancel anytime.
